JP2017522046A - 生物可逆的および生物不可逆的基を有するポリヌクレオチド構築物 - Google Patents

生物可逆的および生物不可逆的基を有するポリヌクレオチド構築物 Download PDF

Info

Publication number
JP2017522046A
JP2017522046A JP2017516650A JP2017516650A JP2017522046A JP 2017522046 A JP2017522046 A JP 2017522046A JP 2017516650 A JP2017516650 A JP 2017516650A JP 2017516650 A JP2017516650 A JP 2017516650A JP 2017522046 A JP2017522046 A JP 2017522046A
Authority
JP
Japan
Prior art keywords
group
alkyl
optionally substituted
aryl
polynucleotide construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017516650A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017522046A5 (2
Inventor
ブラッドショー，コート，ダブリュ．
サカムリ，スクマー
エルテプ，ラクスマン
ラム，ソン
リウ，ディングオ
ミード，ブライアン
イアコノ，ギウセッペ，デッロ
ストック，ジョセフ
リウ，ビン
Original Assignee
ソルスティス バイオロジクス，リミティッド
ソルスティス バイオロジクス，リミティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ソルスティス バイオロジクス，リミティッド, ソルスティス バイオロジクス，リミティッド filed Critical ソルスティス バイオロジクス，リミティッド
Publication of JP2017522046A publication Critical patent/JP2017522046A/ja
Publication of JP2017522046A5 publication Critical patent/JP2017522046A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017516650A 2014-06-06 2015-06-08 生物可逆的および生物不可逆的基を有するポリヌクレオチド構築物 Pending JP2017522046A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462009123P 2014-06-06 2014-06-06
US62/009,123 2014-06-06
PCT/US2015/034749 WO2015188197A2 (en) 2014-06-06 2015-06-08 Polynucleotide constructs having bioreversible and non-bioreversible groups

Publications (2)

Publication Number Publication Date
JP2017522046A true JP2017522046A (ja) 2017-08-10
JP2017522046A5 JP2017522046A5 (2) 2018-07-19

Family

ID=54767614

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017516650A Pending JP2017522046A (ja) 2014-06-06 2015-06-08 生物可逆的および生物不可逆的基を有するポリヌクレオチド構築物

Country Status (7)

Country Link
US (2) US20170114341A1 (2)
EP (1) EP3152308A4 (2)
JP (1) JP2017522046A (2)
CN (1) CN107109405A (2)
AU (1) AU2015269053A1 (2)
CA (1) CA2950960A1 (2)
WO (1) WO2015188197A2 (2)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2019039403A1 (ja) * 2017-08-22 2020-11-26 国立大学法人東海国立大学機構 修飾ポリヌクレオチド
JP2021509402A (ja) * 2017-12-29 2021-03-25 スーチョウ リボ ライフ サイエンス カンパニー、リミテッドＳｕｚｈｏｕ Ｒｉｂｏ Ｌｉｆｅ Ｓｃｉｅｎｃｅ Ｃｏ．， Ｌｔｄ． 複合体及びその調製方法と使用
JP2022515503A (ja) * 2018-12-28 2022-02-18 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
JP2022546055A (ja) * 2019-08-29 2022-11-02 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 化合物、薬物複合体及びその調製方法と使用
WO2023113038A1 (ja) * 2021-12-17 2023-06-22 リードファーマ株式会社 オリゴヌクレオチドの製造方法

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
US20180133327A1 (en) * 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
CA3021580A1 (en) 2015-06-25 2016-12-29 Barry L. Merriman Biomolecular sensors and methods
WO2017100461A1 (en) * 2015-12-08 2017-06-15 Solstice Biologics, Ltd. Polynucleotide constructs having an auxiliary moiety non-bioreversibly linked to an internucleoside phosphate or phosphorothioate
CA3050062A1 (en) 2016-01-14 2017-07-20 Roswell Biotechnologies, Inc. Molecular sensors and related methods
EP3408219B1 (en) 2016-01-28 2022-08-17 Roswell Biotechnologies, Inc Massively parallel dna sequencing apparatus
JP7280590B2 (ja) 2016-01-28 2023-05-24 ロズウェル バイオテクノロジーズ，インコーポレイテッド 大スケールの分子電子工学センサアレイを使用する被分析物を測定するための方法および装置
US10737263B2 (en) 2016-02-09 2020-08-11 Roswell Biotechnologies, Inc. Electronic label-free DNA and genome sequencing
US10597767B2 (en) 2016-02-22 2020-03-24 Roswell Biotechnologies, Inc. Nanoparticle fabrication
PL3429618T3 (pl) 2016-03-16 2024-07-01 Amal Therapeutics Sa Kombinacja modulatora immunologicznego punktu kontrolnego i kompleks zawierający peptyd penetrujący komórkę, cargo i agonistę peptydu tlr do zastosowania w medycynie
US9829456B1 (en) 2016-07-26 2017-11-28 Roswell Biotechnologies, Inc. Method of making a multi-electrode structure usable in molecular sensing devices
EP3491150A4 (en) * 2016-08-01 2020-03-11 Roswell Biotechnologies, Inc MODIFIED NUCLEOTIDE TRIPHOSPHATES FOR MOLECULAR ELECTRONIC SENSORS
CA3033867A1 (en) * 2016-08-17 2018-02-22 Solstice Biologics, Ltd. Polynucleotide constructs
JP7249080B2 (ja) * 2016-08-23 2023-03-30 ディセルナ ファーマシューティカルズ インコーポレイテッド 可逆的に修飾されたオリゴヌクレオチドを含む組成物及びその使用
HUE067838T2 (hu) 2016-09-21 2024-11-28 Amal Therapeutics Sa Egy sejtpenetráló peptidet, egy multiepitópot és egy TLR peptidagonistát tartalmazó fúzió rák kezelésére
CN110268060B (zh) * 2017-01-10 2024-07-26 箭头药业股份有限公司 α-1抗胰蛋白酶(AAT)RNAi物质、包含AAT RNAi物质的组合物和使用方法
WO2018132457A1 (en) 2017-01-10 2018-07-19 Roswell Biotechnologies, Inc. Methods and systems for dna data storage
CN110520517A (zh) 2017-01-19 2019-11-29 罗斯威尔生命技术公司 包括二维层材料的固态测序装置
MX2019012295A (es) * 2017-04-14 2020-02-07 Tollnine Inc Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso.
US10508296B2 (en) 2017-04-25 2019-12-17 Roswell Biotechnologies, Inc. Enzymatic circuits for molecular sensors
KR102879682B1 (ko) 2017-04-25 2025-10-30 로스웰 엠이 아이엔씨. 분자 센서들을 위한 효소 회로들
CA3057155A1 (en) 2017-05-09 2018-11-15 Roswell Biotechnologies, Inc. Binding probe circuits for molecular sensors
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
EP3676389A4 (en) 2017-08-30 2021-06-02 Roswell Biotechnologies, Inc PROCESSIVE ENZYMATIC MOLECULAR ELECTRONIC SENSORS FOR STORING DNA DATA
EP3694990A4 (en) 2017-10-10 2022-06-15 Roswell Biotechnologies, Inc. METHODS, DEVICE AND SYSTEMS FOR AMPLIFICATION-FREE DNA DATA STORAGE
UA128786C2 (uk) 2017-10-20 2024-10-23 Дайсерна Фармасьютикалз, Інк Олігонуклеотид для лікування інфекції гепатиту в
EP3719126B1 (en) 2017-12-01 2025-01-01 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
EP3719127A4 (en) 2017-12-01 2021-10-20 Suzhou Ribo Life Science Co., Ltd. NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH IT, MANUFACTURING METHOD AND USE
CN110944675B9 (zh) 2017-12-01 2024-08-09 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CA3083970A1 (en) 2017-12-01 2019-06-06 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
DK3719128T3 (da) 2017-12-01 2025-03-03 Suzhou Ribo Life Science Co Ltd Dobbelt-strenget oligonukleotid, sammensætning og konjugat bestaende dobbelt-strenget oligonukleotid, fremgangsmåde herfor og anvendelse heraf
KR20200109311A (ko) 2018-01-16 2020-09-22 다이서나 파마수이티컬, 인크. Aldh2 발현을 억제하기 위한 조성물 및 방법
PH12020551219A1 (en) 2018-02-14 2021-04-19 Deep Genomics Incorporated Oligonucleotide therapy for wilson disease
MX2020011570A (es) 2018-05-07 2020-11-24 Alnylam Pharmaceuticals Inc Administracion extrahepatica.
CN112534055A (zh) 2018-07-13 2021-03-19 豪夫迈·罗氏有限公司 用于调节rtel1表达的寡核苷酸
WO2020038377A1 (zh) 2018-08-21 2020-02-27 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的药物组合物和缀合物及其用途
US11896674B2 (en) 2018-09-30 2024-02-13 Suzhou Ribo Life Science Co., Ltd. SiRNA conjugate, preparation method therefor and use thereof
JP7536025B2 (ja) * 2018-10-17 2024-08-19 タラック セラピューティクス，インク． 免疫調節性ポリヌクレオチドコンジュゲートと使用方法
US11249941B2 (en) * 2018-12-21 2022-02-15 Palo Alto Research Center Incorporated Exabyte-scale data storage using sequence-controlled polymers
WO2020135581A1 (zh) * 2018-12-28 2020-07-02 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
EP3908661A1 (en) 2019-02-12 2021-11-17 Dicerna Pharmaceuticals, Inc. Methods and compositions for inhibiting expression of cyp27a1
BR112021019793A2 (pt) 2019-04-04 2021-12-07 Dicerna Pharmaceuticals Inc Composições e métodos para inibir expressão de gene no sistema nervoso central
US12590304B2 (en) 2019-05-22 2026-03-31 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
AU2020280439B2 (en) 2019-05-22 2025-08-14 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
KR20220011689A (ko) 2019-05-22 2022-01-28 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 핵산, 약제학적 조성물, 접합체, 제조 방법, 및 용도
CN113795582B (zh) 2019-05-24 2024-05-24 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
CN113795280B (zh) * 2019-05-24 2024-04-05 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
MX2021015003A (es) 2019-06-06 2022-01-24 Arrowhead Pharmaceuticals Inc Metodos para el tratamiento de la deficiencia de alfa-1 antitripsina (aatd).
CN112390835A (zh) * 2019-08-14 2021-02-23 苏州瑞博生物技术股份有限公司 肝靶向化合物及缀合物
AU2020358016A1 (en) 2019-10-02 2022-04-21 Dicerna Pharmaceuticals, Inc. Chemical modifications of small interfering RNA with minimal fluorine content
CA3164050A1 (en) 2019-12-09 2021-06-17 Empirico Inc. Oligonucleotides for treatment of angiopoietin like 4 (angptl4) related diseases
MX2022007908A (es) 2019-12-24 2022-07-21 Hoffmann La Roche Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv.
EP4081217A1 (en) 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
CA3169523A1 (en) 2020-02-28 2021-09-02 Jaume Pons Transglutaminase-mediated conjugation
US20230287425A1 (en) 2020-03-18 2023-09-14 Dicerna Pharmacuticals Inc. Compositions and methods for inhibiting angptl3 expression
TW202221120A (zh) 2020-08-04 2022-06-01 美商黛瑟納製藥公司 用於治療代謝症候群之組成物及方法
KR20230061389A (ko) 2020-08-04 2023-05-08 다이서나 파마수이티컬, 인크. 올리고뉴클레오티드의 전신 전달
US12435336B2 (en) 2020-08-05 2025-10-07 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting LPA expression
TW202221122A (zh) 2020-08-05 2022-06-01 瑞士商赫孚孟拉羅股份公司 Ｂ型肝炎患者之寡核苷酸治療
EP4225919A1 (en) 2020-10-08 2023-08-16 Dicerna Pharmaceuticals, Inc. Selective delivery of oligonucleotides to glial cells
US20230390403A1 (en) * 2020-10-14 2023-12-07 North Carolina State University Compositions and methods for drug delivery
CA3198230A1 (en) * 2021-01-28 2022-08-04 Jian Chen Conjugate and use thereof
CA3209418A1 (en) 2021-04-14 2022-10-20 Utsav SAXENA Compositions and methods for modulating pnpla3 expression
KR20240101580A9 (ko) 2021-11-11 2025-12-10 에프. 호프만-라 로슈 아게 Hbv 치료를 위한 약학 조합물
JP2024543195A (ja) 2021-12-01 2024-11-19 ディセルナ ファーマシューティカルズ インコーポレイテッド Ａｐｏｃ３発現を調節するための組成物及び方法
US11879125B2 (en) 2022-03-16 2024-01-23 Empirico Inc. GalNAc compositions for improving siRNA bioavailability
US20230374522A1 (en) 2022-04-15 2023-11-23 Dicerna Pharmaceuticals, Inc. Compositions and methods for modulating scap activity
WO2024093947A1 (zh) * 2022-10-31 2024-05-10 大睿生物医药科技(上海)有限公司 向细胞内递送siRNA的前药
WO2024097310A2 (en) * 2022-11-01 2024-05-10 Impilo Therapeutics, Inc. Targeted non-charged-nucleic acid (ncna) delivery and related tumor penetrating nanocomplexes
CN115925586A (zh) * 2022-11-01 2023-04-07 青岛蓝谷多肽生物医药科技有限公司 一种靶向psma的母体及其衍生物的制备方法
TW202430637A (zh) 2022-11-16 2024-08-01 美商戴瑟納製藥股份有限公司 Stat3靶向性寡核苷酸及其用途
CN118852442A (zh) 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
CN116925160B (zh) * 2023-09-15 2023-12-08 天津全和诚科技有限责任公司 一种GalNAc含糖环中间体及其制备方法
WO2025235911A2 (en) * 2024-05-09 2025-11-13 Wave Life Sciences Ltd. Inhibin subunit beta e-related double stranded oligonucleotide compositions and methods relating thereto

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120040459A1 (en) * 2008-09-22 2012-02-16 Rxi Pharmaceuticals Corporation Reduced size self-delivering rnai compounds
US20120142763A1 (en) * 2009-06-01 2012-06-07 The Regents Of The University Of California Nucleic acid delivery compositions and methods of use thereof
WO2014031575A1 (en) * 2012-08-20 2014-02-27 The Regents Of The University Of California Polynucleotides having bioreversible groups

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007249349B2 (en) * 2006-05-11 2012-03-08 Isis Pharmaceuticals, Inc. 5'-Modified bicyclic nucleic acid analogs
EP3066105A4 (en) * 2013-11-06 2017-10-11 Solstice Biologics, Ltd. Polynucleotide constructs having disulfide groups

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120040459A1 (en) * 2008-09-22 2012-02-16 Rxi Pharmaceuticals Corporation Reduced size self-delivering rnai compounds
US20120142763A1 (en) * 2009-06-01 2012-06-07 The Regents Of The University Of California Nucleic acid delivery compositions and methods of use thereof
WO2014031575A1 (en) * 2012-08-20 2014-02-27 The Regents Of The University Of California Polynucleotides having bioreversible groups

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CURR. PROTOC. NUCLEIC ACID CHEM., 2008, VOL.35, 4.33.1-4.33.21, JPN6019028553, ISSN: 0004082367 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2019039403A1 (ja) * 2017-08-22 2020-11-26 国立大学法人東海国立大学機構 修飾ポリヌクレオチド
JP7282379B2 (ja) 2017-08-22 2023-05-29 国立大学法人東海国立大学機構 修飾ポリヌクレオチド
JP2021509402A (ja) * 2017-12-29 2021-03-25 スーチョウ リボ ライフ サイエンス カンパニー、リミテッドＳｕｚｈｏｕ Ｒｉｂｏ Ｌｉｆｅ Ｓｃｉｅｎｃｅ Ｃｏ．， Ｌｔｄ． 複合体及びその調製方法と使用
JP7436030B2 (ja) 2017-12-29 2024-02-21 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 複合体及びその調製方法と使用
JP2022515503A (ja) * 2018-12-28 2022-02-18 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
JP7507495B2 (ja) 2018-12-28 2024-06-28 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
JP2022546055A (ja) * 2019-08-29 2022-11-02 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 化合物、薬物複合体及びその調製方法と使用
WO2023113038A1 (ja) * 2021-12-17 2023-06-22 リードファーマ株式会社 オリゴヌクレオチドの製造方法

Also Published As

Publication number Publication date
CN107109405A (zh) 2017-08-29
WO2015188197A2 (en) 2015-12-10
EP3152308A4 (en) 2017-12-27
CA2950960A1 (en) 2015-12-10
US20200392498A1 (en) 2020-12-17
AU2015269053A1 (en) 2016-12-22
US20170114341A1 (en) 2017-04-27
EP3152308A2 (en) 2017-04-12
WO2015188197A3 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
US20200392498A1 (en) Polynucleotide constructs having bioreversible and non-bioreversible groups
US20160257961A1 (en) Polynucleotide constructs having disulfide groups
AU2013306006B2 (en) Polynucleotides having bioreversible groups
US20240247025A1 (en) Polynucleotide constructs
US20240175019A1 (en) Skeletal Muscle Delivery Platforms and Methods of Use
US20190194655A1 (en) Polynucleotide constructs having an auxiliary moiety non-bioreversibly linked to an internucleoside phosphate or phosphorothioate
CN101506368A (zh) 通过可逆的磷酸三酯电荷中和保护基转导运输核酸
WO2012074038A1 (ja) 修飾１本鎖ポリヌクレオチド
WO2023045995A1 (en) Multivalent Ligand Clusters with Diamine Scaffold for Targeted Delivery of Therapeutic Agents
KR20260056195A (ko) 올리고뉴클레오타이드의 세포내 표적화

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20170511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180608

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191011

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200331